Literature DB >> 16164636

Matrix metalloproteinases and mesangial remodeling in light chain-related glomerular damage.

John Keeling1, Guillermo A Herrera.   

Abstract

BACKGROUND: Matrix metalloproteinases (MMPs) belong to the zinc endopeptidase subgroup of the metalloproteinase superfamily and are primarily involved in extracellular matrix (ECM) remodeling. Alterations of the mesangial ECM in AL-amyloidosis (AL-Am) and light chain deposition disease (LCDD) are crucial in their pathogeneses as two divergent entities.
METHODS: Protein expression patterns of five MMPs (MMP-1, 2, 3, 7, and 9) in renal tissues obtained from autopsies and kidney biopsies, and cultured human mesangial cells (HMCs) treated with light chains obtained from the urines of patients with AL-Am and LCDD were analyzed. MMP mRNA expressions were determined in glomeruli following laser capture microdissection and selective MMP microarray. Zymography was used to assess MMP activity.
RESULTS: The average glomerular MMP expression was 6 times greater in AL-Am than LCDD and negative control renal tissues with different expression profiles: MMP-1, 7 > 9 > 3 > 2, MMP-1 > 2, 9 > 3 > 7, and MMP-2, 3, 7 > 9 > 1, respectively. Microdissected glomeruli and HMCs treated with light chains expressed higher levels of MMP mRNA and proteins in AL-Am than LCDD. Zymography was used to assess activity demonstrating increased MMP-2 in AL-Am.
CONCLUSION: Altered expressions of MMPs play a key role in the pathogenesis of AL-Am and LCDD. MMPs were more highly expressed in AL-Am compared to LCDD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16164636     DOI: 10.1111/j.1523-1755.2005.00571.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  11 in total

1.  Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis.

Authors:  Jennifer Ellis Ward; Ruiyi Ren; Gianluca Toraldo; Pam Soohoo; Jian Guan; Carl O'Hara; Ravi Jasuja; Vickery Trinkaus-Randall; Ronglih Liao; Lawreen H Connors; David C Seldin
Journal:  Blood       Date:  2011-10-12       Impact factor: 22.113

2.  Matrix metalloproteinase-2 dysregulation in type 1 diabetes.

Authors:  Kathryn M Thrailkill; Robert C Bunn; Cynthia S Moreau; Gael E Cockrell; Pippa M Simpson; Hannah N Coleman; J Paul Frindik; Stephen F Kemp; John L Fowlkes
Journal:  Diabetes Care       Date:  2007-06-11       Impact factor: 19.112

Review 3.  Matrix metalloproteinases: their potential role in the pathogenesis of diabetic nephropathy.

Authors:  Kathryn M Thrailkill; R Clay Bunn; John L Fowlkes
Journal:  Endocrine       Date:  2008-10-30       Impact factor: 3.633

4.  Matrix metalloproteinases and their tissue inhibitors in cardiac amyloidosis: relationship to structural, functional myocardial changes and to light chain amyloid deposition.

Authors:  Andreia Biolo; Sujata Ramamurthy; Lawreen H Connors; Carl J O'Hara; Hans K Meier-Ewert; Pamela T Soo Hoo; Douglas B Sawyer; David C Seldin; David S Seldin; Flora Sam
Journal:  Circ Heart Fail       Date:  2008-10-14       Impact factor: 8.790

5.  Doxycycline decreases amyloidogenic light chain-induced autophagy in isolated primary cardiac myocytes.

Authors:  María Valero-Muñoz; Richard M Wilson; Rosa Bretón-Romero; Dominique Croteau; David C Seldin; Flora Sam
Journal:  Int J Cardiol       Date:  2020-07-16       Impact factor: 4.039

6.  Heavy-chain deposition disease: a morphological, immunofluorescence and ultrastructural assessment.

Authors:  Swapnil Rane; Seema Rana; Chetan Mudrabettu; Vivekananda Jha; Kusum Joshi
Journal:  Clin Kidney J       Date:  2012-10

Review 7.  The Many Faces of Matrix Metalloproteinase-7 in Kidney Diseases.

Authors:  Zhao Liu; Roderick J Tan; Youhua Liu
Journal:  Biomolecules       Date:  2020-06-25

8.  Circulating matrix metalloproteinases and tissue inhibitors of metalloproteinases in cardiac amyloidosis.

Authors:  Komei Tanaka; Eric E Essick; Gheorghe Doros; Kahraman Tanriverdi; Lawreen H Connors; David C Seldin; Flora Sam
Journal:  J Am Heart Assoc       Date:  2013-03-12       Impact factor: 5.501

9.  Rationale and design of DUAL study: Doxycycline to Upgrade response in light chain (AL) amyloidosis (DUAL): A phase 2 pilot study of a two-pronged approach of prolonged doxycycline with plasma cell-directed therapy in the treatment of AL amyloidosis.

Authors:  Anita D'Souza; Kathryn Flynn; Saurabh Chhabra; Binod Dhakal; Mehdi Hamadani; Kirsten Jacobsen; Marcelo Pasquini; Dorothee Weihrauch; Parameswaran Hari
Journal:  Contemp Clin Trials Commun       Date:  2017-08-24

10.  Cardiac Fibrosis in Proteotoxic Cardiac Disease is Dependent Upon Myofibroblast TGF -β Signaling.

Authors:  Bidur Bhandary; Qinghang Meng; Jeanne James; Hanna Osinska; James Gulick; Iñigo Valiente-Alandi; Michelle A Sargent; Md Shenuarin Bhuiyan; Burns C Blaxall; Jeffery D Molkentin; Jeffrey Robbins
Journal:  J Am Heart Assoc       Date:  2018-10-16       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.